U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C40H63N3O4S2
Molecular Weight 714.076
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIPOTIAZINE PALMITATE

SMILES

CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2C3=CC(=CC=C3SC4=C2C=CC=C4)S(=O)(=O)N(C)C)CC1

InChI

InChIKey=KTOYYUONFQWSMW-UHFFFAOYSA-N
InChI=1S/C40H63N3O4S2/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-22-40(44)47-32-27-34-25-30-42(31-26-34)28-19-29-43-36-20-17-18-21-38(36)48-39-24-23-35(33-37(39)43)49(45,46)41(2)3/h17-18,20-21,23-24,33-34H,4-16,19,22,25-32H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C40H63N3O4S2
Molecular Weight 714.076
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.ndrugs.com/?s=pipotiazine | https://www.ncbi.nlm.nih.gov/pubmed/2875894

Pipotiazine (Piportil), also known as Pipothiazine, is a typical antipsychotic of the phenothiazine class used in the United Kingdom and other countries for the treatment of schizophrenia. Its properties are similar to those of chlorpromazine. Piportil® L4 (pipotiazine palmitate) is the palmitic ester of pipotiazine, a piperidine phenothiazine with antipsychotic properties and weak sedative activity. The esterification of pipotiazine is responsible for its prolonged duration of action. The onset of action appears usually within the first 2 to 3 days after injection and the effects of the drug on psychotic symptoms are significant within one week. Improvement in symptomatology lasts from 3 to 6 weeks, but adequate control may frequently be maintained with one injection every 4 weeks. However, in view of the variations in individual response, careful supervision is required throughout treatment. Piportil L4 has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, Piportil L4 appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extrapyramidal reactions.

Originator

Sources: Therapie Volume 28, Issue 4, Pages 753-63, Journal, 1973

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.2 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PIPORTIL L4

Approved Use

INDICATIONS: Piportil L4 (pipotiazine palmitate) is indicated in the maintenance treatment of chronic non-agitated schizophrenic patients.
PubMed

PubMed

TitleDatePubMed
Localization and function of the D3 dopamine receptor.
1992 Feb
Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review.
2006 Sep
Imputation methods for missing outcome data in meta-analysis of clinical trials.
2008
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
2008 Dec 22
Relationship between obesity and antipsychotic drug use in the adult population: a longitudinal, retrospective claim database study in Primary Care settings.
2008 Feb
[Priapism associated with antipsychotic medications: a series of four patients].
2008 Nov
Availability and use of essential medicines in China: manufacturing, supply, and prescribing in Shandong and Gansu provinces.
2010 Jul 17
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: http://www.ndrugs.com/?s=pipotiazine
Oral: 5-20 mg daily. Severe: 30 mg daily for brief periods. Intramuscular: As pipotiazine palmitate: Initially, 25 mg as test dose followed by 25-50 mg after 4 to 7 days. Adjust in increments of 25-50 mg according to response every 4 wk.
Route of Administration: Other
In Vitro Use Guide
Rats brain striata were dissected out and put in ice-cold 0.25 M sucrose containing 3 mM imidazole, pH 7.4. The striata were then homogenized by 10 strokes of the right pestle of a Duncan homogenizer. The homogenate was fractionated at 0-4°C by differential centrifugation. The assays were performed in 50 mM Tris-HC1 buffer pH 7.1 containing (mM): 120 NaC1, 5 KC1, 2 CaC12, 1 MgC12, 0.1% ascorbic acid and 10 mkM pargyline. The final protein concentration was 0.29 mg/ml. After 5 rain preincubation at 37°C, [3H]N.propylnorapomorphine (final concentration 0.3 nM) and different concentrations of unlabeled drugs were added. After 24 rain incubation at 37°C, the samples were filtered through Whatman GF/B glass fibre filters. Radioactivity retained on the filters was measured by liquid scintillation counting.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:25:23 GMT 2023
Edited
by admin
on Fri Dec 15 15:25:23 GMT 2023
Record UNII
4Q3H01QRMI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PIPOTIAZINE PALMITATE
MART.   USAN   WHO-DD  
USAN  
Official Name English
PIPOTIAZINE PALMITIC ESTER [MI]
Common Name English
PIPOTIAZINE PALMITIC ESTER
MI  
Common Name English
PIPOTIAZINE PALMITATE [USAN]
Common Name English
PIPORTIL DEPOT
Brand Name English
Pipotiazine palmitate [WHO-DD]
Common Name English
RP-19552
Code English
19552 RP
Code English
RP 19552
Code English
IL-19552
Code English
PIPOTIAZINE PALMITATE [MART.]
Common Name English
10-[3-[4-(2-Hydroxyethyl)piperidino]propyl]-N,N-dimethylphenothiazine-2-sulfonamide palmitate (ester)
Common Name English
HEXADECANOIC ACID, 2-(1-(3-(2-((DIMETHYLAMINO)SULFONYL)-10H-PHENOTHIAZIN-10-YL)PROPYL)-4-PIPERIDINYL)ETHYL ESTER
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66883
Created by admin on Fri Dec 15 15:25:24 GMT 2023 , Edited by admin on Fri Dec 15 15:25:24 GMT 2023
NCI_THESAURUS C29710
Created by admin on Fri Dec 15 15:25:24 GMT 2023 , Edited by admin on Fri Dec 15 15:25:24 GMT 2023
Code System Code Type Description
MERCK INDEX
m8865
Created by admin on Fri Dec 15 15:25:24 GMT 2023 , Edited by admin on Fri Dec 15 15:25:24 GMT 2023
PRIMARY Merck Index
CAS
37517-26-3
Created by admin on Fri Dec 15 15:25:24 GMT 2023 , Edited by admin on Fri Dec 15 15:25:24 GMT 2023
PRIMARY
DRUG BANK
DBSALT001196
Created by admin on Fri Dec 15 15:25:24 GMT 2023 , Edited by admin on Fri Dec 15 15:25:24 GMT 2023
PRIMARY
EVMPD
SUB03860MIG
Created by admin on Fri Dec 15 15:25:24 GMT 2023 , Edited by admin on Fri Dec 15 15:25:24 GMT 2023
PRIMARY
ChEMBL
CHEMBL2106439
Created by admin on Fri Dec 15 15:25:24 GMT 2023 , Edited by admin on Fri Dec 15 15:25:24 GMT 2023
PRIMARY
DRUG CENTRAL
2193
Created by admin on Fri Dec 15 15:25:24 GMT 2023 , Edited by admin on Fri Dec 15 15:25:24 GMT 2023
PRIMARY
PUBCHEM
37767
Created by admin on Fri Dec 15 15:25:24 GMT 2023 , Edited by admin on Fri Dec 15 15:25:24 GMT 2023
PRIMARY
FDA UNII
4Q3H01QRMI
Created by admin on Fri Dec 15 15:25:24 GMT 2023 , Edited by admin on Fri Dec 15 15:25:24 GMT 2023
PRIMARY
NCI_THESAURUS
C87712
Created by admin on Fri Dec 15 15:25:24 GMT 2023 , Edited by admin on Fri Dec 15 15:25:24 GMT 2023
PRIMARY
EPA CompTox
DTXSID5048970
Created by admin on Fri Dec 15 15:25:24 GMT 2023 , Edited by admin on Fri Dec 15 15:25:24 GMT 2023
PRIMARY
SMS_ID
100000085290
Created by admin on Fri Dec 15 15:25:24 GMT 2023 , Edited by admin on Fri Dec 15 15:25:24 GMT 2023
PRIMARY
RXCUI
235745
Created by admin on Fri Dec 15 15:25:24 GMT 2023 , Edited by admin on Fri Dec 15 15:25:24 GMT 2023
PRIMARY RxNorm
ECHA (EC/EINECS)
253-536-4
Created by admin on Fri Dec 15 15:25:24 GMT 2023 , Edited by admin on Fri Dec 15 15:25:24 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY